Coronavirus Update: Roche's Actemra Shows No Benefit In Early COVID-19 Pneumonia Study
Plus Synairgen Expands Home-based Interferon Trial
Roche's Actemra was identified early on in the pandemic as a possible treatment for patients with COVID-19 induced pneumonia. As larger studies await read-out, data from an Italian study disappoints.
You may also be interested in...
The RECOVERY trial has produced clear results for the cheap steroid treatment dexamethasone. What does it mean for Gilead's antiviral remdesivir?
Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1 Billion Vaccine Adjuvant Doses
Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.
Recent executive moves in the industry include C-suite changes at NervGen Pharma and Phathom Pharmaceuticals and Clarity Pharmaceuticals. Meanwhile, new directors were appointed at Janux Therapeutics and PepGen.